CX-516
From Wikipedia, the free encyclopedia
 |
|
|
CX-516
|
|
| Systematic (IUPAC) name | |
| 6-(piperidin-1-ylcarbonyl)quinoxaline | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C14H15N3O |
| Mol. mass | 241.289 g/mol |
| Synonyms | Ampalex, CX-516 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 45 minutes |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Investigational New Medicine |
| Routes | ? |
CX-516 is an ampakine compound that works as an AMPA modulator and is being developed by a collaboration of Cortex and Shire and Servier. It was researched as a treatment for Alzheimer's disease, under the brand name Ampalex, and was also being examined as a treatment for ADHD.
CX-516 was the first ampakine compound developed by Cortex and while it showed good in vitro activity and positive results in animal tests, the human trials proved disappointing due mainly to low potency and short half-life. However CX-516 is still widely used in animal research into the ampakine drugs and is the standard reference compound that newer, more potent drugs of this class such as farampator and CX-717 are compared to.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
[edit] References
[edit] See also
|
|||||||||||||||||||||||
